Gold soars to record high over $3,900/oz amid yen slump, US rate cut bets
Investing.com - Guggenheim raised its price target on Maze Therapeutics (NASDAQ:MAZE) to $34.00 from $19.00 on Monday, while maintaining a Buy rating on the stock. The company, currently valued at $1 billion, has seen remarkable momentum with a 55% surge in the past week. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $27 to $50.
The price target increase follows encouraging data from Maze’s healthy volunteer study, which showed urinary phenylalanine (Phe) increases of 24 to 55 times baseline levels with the company’s drug candidate MZ782.
Guggenheim noted that these results exceeded the 10-times threshold analysts were looking for, potentially indicating a superior profile compared to competing treatments for phenylketonuria (PKU).
The firm highlighted that MZ782’s pharmacokinetic profile shows a half-life of approximately 11 hours versus competitors’ 6 hours, giving Maze flexibility to explore either twice-daily or once-daily dosing regimens in future trials.
Guggenheim also pointed to analysis of estimated glomerular filtration rate (eGFR) data, suggesting that initial dips observed in healthy volunteers may serve as a positive signal for the drug’s potential in chronic kidney disease (CKD) applications.
In other recent news, Maze Therapeutics has received a boost in analyst ratings following positive developments in its drug programs. H.C. Wainwright raised its price target for Maze Therapeutics to $50 from $34, maintaining a Buy rating, due to promising Phase 1 data from its MZE782 program. This data highlighted robust pharmacodynamic signals that surpassed benchmarks set by competitors. Similarly, BTIG increased its price target for Maze to $37 from $30, also maintaining a Buy rating, after observing significant increases in urinary phenylalanine excretion from the MZE782 drug candidate. This performance exceeded management’s previous guidance, particularly in phenylketonuria and chronic kidney disease contexts. Additionally, BTIG initiated coverage of Maze Therapeutics with a Buy rating and a $30 price target, emphasizing the potential of Maze’s MZE829 drug candidate in treating APOL1-mediated kidney disease. In corporate news, Maze Therapeutics has appointed Misbah Tahir as its new chief financial officer, effective immediately. Tahir brings a wealth of experience from his previous roles at IGM Biosciences, Dermira, and other companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.